Cancer is a complex disease, and treating it is difficult due to the variable efficacy of conventional anticancer drugs. A two-drug cocktail hybrid approach is a recent drug discovery strategy that involves combining two drug pharmacophores into a single molecule. The hybrid molecule acts on multiple targets simultaneously through distinct modes of action, resulting in greater efficacy and less susceptibility to resistance. As a result, there is enormous potential for using hybrid compounds to address the current challenges in cancer medicine. Recent research has used this technique to discover some intriguing molecules with significant anticancer properties. We present data on a number of promising hybrid anti-proliferative/ anti-tumor agents developed over the previous ten years in this study. Quinazoline, indole, carbazole, pyrimidine, quinoline, quinone, imidazole, selenium, platinum, hydroxamic acid, ferrocene, curcumin, triazole, benzimidazole, isatin, pyrrolo benzodiazepine (PBD), chalcone, coumarin, nitrogen mustard, pyrazole, and pyridine-based anticancer hybrids are examples. Overall, this review demonstrates the potential benefits of combining pharmacophoric subunits from various known chemical prototypes to create more potent and precise hybrid compounds. This is useful information for researchers working on complex diseases like cancer.
HTML PDFShare this article
Medicinal Chemistry received 6627 citations as per Google Scholar report
